ArticleBMC infectious diseases2025
Evaluation of a novel comprehensive sexual health e-testing pathway to inform state-wide roll out in new South wales, Australia.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
aimTo evaluate the acceptability of MyCheck for asymptomatic sexually transmissible infections (STIs) testing.
backgroundRegular testing for STIs in at-risk populations is recommended by Australian guidelines as many STIs are asymptomatic. Consequently, MyCheck was developed to enhance access by combining a telehealth consultation with direct referral to pathology, avoiding the need for in-person clinic visits. MyCheck was piloted at Sydney Sexual Health Centre (SSHC)-the largest publicly funded urban sexual health clinic in New South Wales-between June 2021 and February 2022.
methodsMyCheck integrated telehealth assessment with electronic referrals to over 500 pathology centres and automated result entry into the clinic's patient management system. Staff initiated MyCheck testing offers to asymptomatic clients without complex care needs. Evaluation was based on clinic data and client surveys.
resultsStaff offered MyCheck to 9.8% (718/7340) of eligible clients. Of those, approximately two-thirds (472/718) accepted the offer and two-thirds (315/472) attended a pathology collection center. Females were more likely to accept the offer of MyCheck compared to males (RR: 1.2, 95% CI: 1.1-1.4). Clients who arrived in Australia more than 10 years ago were more likely (RR: 1.2, 95% CI: 1.0-1.4) to accept MyCheck testing compared to those who recently arrived. Clients who were on HIV-Pre exposure prophylaxis (PrEP) were less likely to accept MyCheck testing (RR: 0.8, 95% CI: 0.6-1.0) compared with clients not on PrEP. Relative to other existing asymptomatic testing services, the majority of MyCheck survey respondents rated MyCheck highly on location of pathology collection centers, quick test turnaround, and appointment availability. However, only ~50% of clients rated support for questions about safe and stigma free environment, and familiarity highly. Of all the visits to a pathology collection centre, 17.8% (56/315), resulted in a positive STI diagnosis (40 chlamydia, 26 gonorrhoea, 3 Mycoplasma genitalium, and one case of early latent syphilis), with all diagnoses linked to treatment.
conclusionsMyCheck was well-received by clients and effective as an STI screening and management testing pathway. Offer of MyCheck to clients was a limiting factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.